Three Years Follow-up Results of Ranibizumab Treatment for Choroidal Neovascularization Secondary to Pathologic Myopia

Abstract

Treating CNV secondary to PM with ranibizumab during a follow-up of 36 months, we found considerable improvement of visual acuity. Compared to treatment of CNV secondary to exudative age-related macular degeneration, CNVs secondary to PM seem to respond faster to ranibizumab treatment and less injections are neccessary to reach stabilization.

Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization

“…Yet, in a recent retrospective study, Ruiz Moreno et al [11] analyzed the outcomes 4 years after initial treatment with intravitreal bevacizumab or ranibizumab, and found that both drugs had significant and lasting efficacy in 92 patients affected by subfoveal myopic CNV. Further analysis of follow-ups lasting between 36 and 48 months shows that the maintenance of significant visual gains is supported by the studies of Hefner et al [27], Peiretti et al [29], and Franquera et al [28]. In particular, Franquera et al [28], analyzing 40 patients affected by subfoveal or juxtafoveal myopic CNV, found not only significant improvements but also increasing visual gains over the course of follow-up, up to their 36-month examination.…”

“…Data in the literature seem to show that their positive effects are maintained even after longer follow-up periods, although some patient series have failed to demonstrate long-term maintenance of the oneyear visual gain [12,[19][20][21][22][23][24][25][26][27][28][29][30][31]. In particular, Voykov et al [23] and Ikuno et al [24] showed a loss of visual benefits at 24-month examination.…”

“…Controversy over the long-term efficacy of anti-VEGFs persists. In fact, the maintenance of significant visual gains, while supported by the studies of Ruiz Moreno et al [11], Hefner et al [27], Franquera et al [28], Peiretti et al [29] and Yang et al [30], with follow-up periods ranging from 36 to 48 months, has been questioned by Oishi et al [31], who found a drop in the visual benefits of intravitreal injection after 4 years, mainly due to the development/ enlargement of chorioretinal atrophy. These different outcomes might be explained by the heterogenicity of the abovementioned studies in terms of the number of patients enrolled, the anti-VEGF agent used (bevacizumab or ranibizumab), the loading dose (one or three injections), the anti-VEGF dosage, and the inclusion or exclusion of previously PDT-treated eyes in the evaluation .…”

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularizations Associated with Pathologic Myopia: A Prospective Study

“…As in the treatment of exudative age-related macular degeneration, most authors advocate the use of a PRN regime, where injections are repeated based on predefined reinjection criteria. While an initial ‘upload' with 3 monthly injections at the beginning of treatment is considered a standard treatment in exudative age-related macular degeneration, a swifter treatment response has been observed in pathologic myopia so that most authors recommend a PRN regime immediately after the first injection [25,26]. …”

Modern views on myopic maculopathy

“…По данным L. Hefner [51], для купирования активности новообразованных сосудов тре-буется в среднем 3 инъекции (диапазон 1-8) в течение 39,6 мес (диапазон . Перед первой инъекцией острота зрения составляла (LogMAR) 0,69±0,26, через 1 мес она улучшилась до 0,39±0,23 (р=0,002), через 3 мес -до 0,30±0,22 (р=0,002), 6 мес -до 0,30±0,22 (р=0,002).…”